vs
Side-by-side financial comparison of Fortive (FTV) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Fortive is the larger business by last-quarter revenue ($1.1B vs $622.0M, roughly 1.7× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 12.8%, a 21.7% gap on every dollar of revenue. On growth, Fortive posted the faster year-over-year revenue change (7.7% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -17.0%).
Fortive Corporation is an American industrial technology conglomerate company headquartered in Everett, Washington. The company specializes in providing essential technologies for connected workflow solutions; designing, developing, manufacturing and distributing professional and engineered products, software and services. Their products and services are split into three strategic segments; Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. As of Decem...
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
FTV vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $622.0M |
| Net Profit | $136.4M | $214.2M |
| Gross Margin | 63.2% | — |
| Operating Margin | 17.9% | 62.4% |
| Net Margin | 12.8% | 34.4% |
| Revenue YoY | 7.7% | 4.8% |
| Net Profit YoY | 21.1% | 2.9% |
| EPS (diluted) | $0.44 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $622.0M | ||
| Q3 25 | $1.0B | $609.3M | ||
| Q2 25 | $1.5B | $578.7M | ||
| Q1 25 | $1.5B | $568.2M | ||
| Q4 24 | $1.6B | $593.6M | ||
| Q3 24 | $1.5B | $564.7M | ||
| Q2 24 | $1.6B | $537.3M |
| Q1 26 | $136.4M | — | ||
| Q4 25 | $185.7M | $214.2M | ||
| Q3 25 | $55.0M | $288.2M | ||
| Q2 25 | $166.6M | $30.2M | ||
| Q1 25 | $171.9M | $238.3M | ||
| Q4 24 | $208.8M | $208.2M | ||
| Q3 24 | $221.6M | $544.0M | ||
| Q2 24 | $195.1M | $102.0M |
| Q1 26 | 63.2% | — | ||
| Q4 25 | 63.2% | — | ||
| Q3 25 | 63.2% | — | ||
| Q2 25 | 59.0% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | 60.3% | — | ||
| Q3 24 | 60.0% | — | ||
| Q2 24 | 59.8% | — |
| Q1 26 | 17.9% | — | ||
| Q4 25 | 20.1% | 62.4% | ||
| Q3 25 | 15.5% | 70.1% | ||
| Q2 25 | 14.6% | 36.3% | ||
| Q1 25 | 15.8% | 94.0% | ||
| Q4 24 | 19.0% | 60.9% | ||
| Q3 24 | 19.3% | — | ||
| Q2 24 | 19.4% | 50.2% |
| Q1 26 | 12.8% | — | ||
| Q4 25 | 16.5% | 34.4% | ||
| Q3 25 | 5.4% | 47.3% | ||
| Q2 25 | 11.0% | 5.2% | ||
| Q1 25 | 11.7% | 41.9% | ||
| Q4 24 | 12.9% | 35.1% | ||
| Q3 24 | 14.4% | 96.3% | ||
| Q2 24 | 12.6% | 19.0% |
| Q1 26 | $0.44 | — | ||
| Q4 25 | $0.60 | $0.49 | ||
| Q3 25 | $0.16 | $0.67 | ||
| Q2 25 | $0.49 | $0.07 | ||
| Q1 25 | $0.50 | $0.55 | ||
| Q4 24 | $0.60 | $0.46 | ||
| Q3 24 | $0.63 | $1.21 | ||
| Q2 24 | $0.55 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $356.1M | $618.7M |
| Total DebtLower is stronger | $3.5B | $9.0B |
| Stockholders' EquityBook value | $6.1B | $9.7B |
| Total Assets | $11.6B | $19.6B |
| Debt / EquityLower = less leverage | 0.57× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $356.1M | — | ||
| Q4 25 | $375.5M | $618.7M | ||
| Q3 25 | $430.8M | $938.9M | ||
| Q2 25 | $1.8B | $631.9M | ||
| Q1 25 | $892.1M | $1.1B | ||
| Q4 24 | $813.3M | $929.0M | ||
| Q3 24 | $811.3M | $950.1M | ||
| Q2 24 | $644.1M | $1.8B |
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.2B | $9.0B | ||
| Q3 25 | $3.3B | $8.9B | ||
| Q2 25 | $4.8B | $8.0B | ||
| Q1 25 | $3.9B | $7.6B | ||
| Q4 24 | $3.7B | $7.6B | ||
| Q3 24 | $3.9B | $7.6B | ||
| Q2 24 | $3.8B | $7.6B |
| Q1 26 | $6.1B | — | ||
| Q4 25 | $6.5B | $9.7B | ||
| Q3 25 | $6.5B | $9.6B | ||
| Q2 25 | $10.4B | $9.5B | ||
| Q1 25 | $10.2B | $9.8B | ||
| Q4 24 | $10.2B | $10.3B | ||
| Q3 24 | $10.6B | $10.3B | ||
| Q2 24 | $10.5B | $9.8B |
| Q1 26 | $11.6B | — | ||
| Q4 25 | $11.7B | $19.6B | ||
| Q3 25 | $11.9B | $19.3B | ||
| Q2 25 | $18.2B | $18.3B | ||
| Q1 25 | $17.1B | $17.6B | ||
| Q4 24 | $17.0B | $18.2B | ||
| Q3 24 | $17.5B | $18.0B | ||
| Q2 24 | $17.3B | $17.7B |
| Q1 26 | 0.57× | — | ||
| Q4 25 | 0.50× | 0.92× | ||
| Q3 25 | 0.51× | 0.93× | ||
| Q2 25 | 0.46× | 0.84× | ||
| Q1 25 | 0.38× | 0.78× | ||
| Q4 24 | 0.36× | 0.74× | ||
| Q3 24 | 0.37× | 0.74× | ||
| Q2 24 | 0.36× | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $234.8M | $827.1M |
| Free Cash FlowOCF − Capex | $193.8M | — |
| FCF MarginFCF / Revenue | 18.1% | — |
| Capex IntensityCapex / Revenue | 2.5% | — |
| Cash ConversionOCF / Net Profit | 1.72× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $935.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $234.8M | — | ||
| Q4 25 | $1.1B | $827.1M | ||
| Q3 25 | $164.4M | $702.6M | ||
| Q2 25 | $311.2M | $364.0M | ||
| Q1 25 | $241.7M | $596.1M | ||
| Q4 24 | $502.2M | $742.5M | ||
| Q3 24 | $459.0M | $703.6M | ||
| Q2 24 | $308.9M | $658.2M |
| Q1 26 | $193.8M | — | ||
| Q4 25 | $313.8M | — | ||
| Q3 25 | $153.1M | — | ||
| Q2 25 | $274.5M | — | ||
| Q1 25 | $215.0M | — | ||
| Q4 24 | $465.2M | — | ||
| Q3 24 | $431.2M | — | ||
| Q2 24 | $279.7M | — |
| Q1 26 | 18.1% | — | ||
| Q4 25 | 28.0% | — | ||
| Q3 25 | 14.9% | — | ||
| Q2 25 | 18.1% | — | ||
| Q1 25 | 14.6% | — | ||
| Q4 24 | 28.7% | — | ||
| Q3 24 | 28.1% | — | ||
| Q2 24 | 18.0% | — |
| Q1 26 | 2.5% | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 1.9% | — |
| Q1 26 | 1.72× | — | ||
| Q4 25 | 5.83× | 3.86× | ||
| Q3 25 | 2.99× | 2.44× | ||
| Q2 25 | 1.87× | 12.06× | ||
| Q1 25 | 1.41× | 2.50× | ||
| Q4 24 | 2.41× | 3.57× | ||
| Q3 24 | 2.07× | 1.29× | ||
| Q2 24 | 1.58× | 6.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FTV
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
